专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US08168584B2 Methods of treating age-related macular degeneration by compstatin and analogs thereof 有权
标题翻译：用化合物及其类似物治疗年龄相关性黄斑变性的方法
公开(公告)号：US08168584B2
公开(公告)日：2012-05-01
申请号：US11544389
申请日：2006-10-06
申请人： Pascal Deschatelets , Paul Olson , Cedric Francois
发明人： Pascal Deschatelets , Paul Olson , Cedric Francois
IPC分类号： A61K38/12
CPC分类号： C07K7/08 , A61F9/0008 , A61K9/0019 , A61K9/0048 , A61K9/0051 , A61K31/00 , A61K31/7105 , A61K38/00 , A61K38/08 , A61K38/10 , A61K38/12 , A61K38/17 , A61K39/3955 , A61K49/0008 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K2319/01 , G01N33/6872 , G01N2333/4704 , G01N2500/04 , G01N2500/20
摘要： The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and/or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.
摘要翻译：本发明的特征在于使用化合物抑制剂和补体抑制类似物来治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性，脉络膜新生血管形成和/或视网膜新生血管形成的其它病症。本发明还提供了包含抑制剂或其补体抑制类似物和第二治疗剂的组合物。本发明还提供了包含抑制抑制剂或其补体抑制类似物和凝胶形成材料例如可溶性胶原蛋白的组合物，以及施用组合物的方法。

12. 发明申请

US20100166862A1 Local Complement Inhibition for Treatment of Complement-Mediated Disorders 有权
标题翻译：局部补体抑制治疗补体介导性疾病
公开(公告)号：US20100166862A1
公开(公告)日：2010-07-01
申请号：US12525799
申请日：2008-02-05
申请人： Cedric Francois , Pascal Deschatelets , Paul Olson
发明人： Cedric Francois , Pascal Deschatelets , Paul Olson
IPC分类号： A61K38/10 , A61K9/10 , A61K39/395 , A61K38/12 , A61K38/16 , A61K31/7088 , A61P19/02 , A61P11/06 , A61P25/28 , A61P25/16 , A61P9/00 , A61P17/06 , A61P27/02 , A61P27/06 , A61P37/00
CPC分类号： A61K39/3955 , A61K38/12 , A61K38/17 , A61K45/06 , C07K7/64 , C07K14/435
摘要： The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof.
摘要翻译：本发明的特征在于用于治疗补体介导的病症的补体抑制剂的局部施用。在某些实施方案中，本发明特征在于抑制一种或多种局部产生的补体蛋白的活化本发明提供持续释放制剂和包含补体抑制剂的装置及其使用方法。

13. 发明授权

US07093555B1 Docking system 失效
标题翻译：对接系统
公开(公告)号：US07093555B1
公开(公告)日：2006-08-22
申请号：US11148943
申请日：2005-06-09
申请人： Donald Olson , Paul Olson
发明人： Donald Olson , Paul Olson
IPC分类号： B60P3/10
CPC分类号： B60P3/1075 , B60P3/1066
摘要： A docking system for a watercraft having a cross member carrying a tow hook cart to engage a bow eye on the watercraft and thereafter permit docking of the watercraft. The cross member is supported by at least one upright structure and may include a latch mechanism to release the cross member to swing away after the hook engages the eye. Alternatively, a cross member may be supported on both ends and may be pulled out of the way by the tow rope or rotated over the eye by a latch tripped after the hook engages the eye.
摘要翻译：一种用于船舶的对接系统，其具有携带牵引车的横向构件，以接合船只上的弓形眼睛，然后允许船舶对接。横向构件由至少一个直立结构支撑并且可以包括闩锁机构，以在钩与眼睛接合之后释放横向构件以摆动。或者，横向构件可以被支撑在两端上，并且可以被牵引绳拉出，或者在钩与眼睛接合之后被闩锁翻转，从而在眼睛上旋转。

14. 发明申请

US20060142191A1 Viral complement control proteins for eye disorders 失效
标题翻译：用于眼睛疾病的病毒补体对照蛋白
公开(公告)号：US20060142191A1
公开(公告)日：2006-06-29
申请号：US11247886
申请日：2005-10-08
申请人： Cedric Francois , Pascal Deschatelets , Paul Olson
发明人： Cedric Francois , Pascal Deschatelets , Paul Olson
IPC分类号： A61K38/16
CPC分类号： A61K38/162 , C07K14/005 , C07K2319/33 , C12N2710/24122
摘要： The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.
摘要翻译：本发明提供用于治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性或脉络膜新生血管形成的其它病症的组合物和方法。某些组合物包含痘病毒补体对照蛋白或其补体结合片段或变体。其他组合物包含与结合存在于细胞或非细胞分子实体的表面或其表面上的组分连接的部分的痘病毒补体对照蛋白，例如存在于患有年龄相关性黄斑的风险的患者的眼睛中的组分变性或相关病症或脉络膜新生血管形成。某些方法包括向受试者施用痘病毒补体对照蛋白或补体结合片段或其变体。

15. 发明申请

US20050113297A1 Compositions and methods for enhancing phagocytosis or phagocyte activity 有权
标题翻译：用于增强吞噬作用或吞噬细胞活性的组合物和方法
公开(公告)号：US20050113297A1
公开(公告)日：2005-05-26
申请号：US10923940
申请日：2004-08-23
申请人： Cedric Francois , Pascal Deschatelets , Paul Olson , Alec Machiels
发明人： Cedric Francois , Pascal Deschatelets , Paul Olson , Alec Machiels
IPC分类号： A61K38/17 , A61K47/48 , C12N5/08
CPC分类号： B82Y5/00 , A61K47/544 , A61K47/62 , A61K47/6911 , A61K47/6913
摘要： The present invention provides a system for enhancing clearance or destruction of undesirable cells or noncellular molecular entities by tagging such cells or noncellular molecular entities with a marker that targets the cells or noncellular molecular entities for phagocytosis (phagocytic marker). The target cells can be, for example, endothelial cells, tumor cells, leukocytes, or virus-infected cells. In certain embodiments of the invention the tagging is accomplished by administering a composition comprising an antibody or ligand linked to the phagcytotic marker, wherein the antibody or ligand binds to a cell type specific marker present on or in the cell surface of a target cell. In preferred embodiments of the invention, the phagocytic marker comprises phosphatidylserine or a group derived from phosphatidylserine, thrombospondin-1, annexin I, or a derivative of any of these.
摘要翻译：本发明提供了一种用于通过用靶向细胞或非细胞分子实体进行吞噬作用（吞噬标记）的标记来标记这样的细胞或非细胞分子实体来增强不需要的细胞或非细胞分子实体的清除或破坏的系统。靶细胞可以是例如内皮细胞，肿瘤细胞，白细胞或病毒感染的细胞。在本发明的某些实施方案中，标记通过施用包含与噬菌体标记物连接的抗体或配体的组合物来实现，其中所述抗体或配体结合存在于靶细胞的细胞表面上或细胞表面的细胞类型特异性标志物。在本发明的优选实施方案中，吞噬标记物包含磷脂酰丝氨酸或衍生自磷脂酰丝氨酸，血小板反应素-1，膜联蛋白I或其任何衍生物的基团。

16. 发明授权

US09291622B2 Complement assays and uses thereof 有权
标题翻译：补体测定及其用途
公开(公告)号：US09291622B2
公开(公告)日：2016-03-22
申请号：US13321522
申请日：2010-05-21
申请人： Zhouning Zhang , Cedric Francois , Pascal Deschatelets , Paul Olson
发明人： Zhouning Zhang , Cedric Francois , Pascal Deschatelets , Paul Olson
IPC分类号： G01N33/564 , C07K16/18 , G01N33/68
CPC分类号： G01N33/566 , C07K16/18 , G01N33/564 , G01N33/6893 , G01N2333/4716 , G01N2800/16 , G01N2800/164 , G01N2800/50 , G01N2800/52 , G01N2800/7042
摘要： The present invention provides methods for assessing complement activation and methods for assessing the ability of an agent or condition of interest to modulate complement activation. The present invention provides methods for assessing whether a subject has or is at increased risk of developing a complement-mediated disorder, e.g., age-related macular degeneration (AMD). Also provided are kits containing materials useful for performing the methods.
摘要翻译：本发明提供了用于评估补体活化的方法和评估感兴趣的药剂或病症调节补体活化能力的方法。本发明提供用于评估受试者是否具有发生补体介导的病症（例如年龄相关性黄斑变性（AMD））的风险增加的方法。还提供了包含用于执行方法的材料的试剂盒。

17. 发明授权

US08865164B2 Detecting complement activation 有权
标题翻译：检测补体激活
公开(公告)号：US08865164B2
公开(公告)日：2014-10-21
申请号：US13461709
申请日：2012-05-01
申请人： Paul Olson , Don W. Moss , Nicholas Staten
发明人： Paul Olson , Don W. Moss , Nicholas Staten
IPC分类号： A61K39/395 , G01N33/00 , G01N33/53 , G01N33/566 , G01N33/564
CPC分类号： G01N33/564 , G01N33/5306 , G01N2333/4716 , G01N2800/104 , G01N2800/125 , G01N2800/26 , G01N2800/52
摘要： Methods of detecting complement activation including steps of detecting in a sample from a subject a level of iC3b wherein the detecting involves specific interaction between the iC3b and a non-cross-reactive antibody thereto, comparing the detected level with a reference level, which reference level is within a range of about 10 ng/ml to about 5,000 ng/ml, wherein determination that the detected level is above the reference level indicates that the subject is suffering from or susceptible to undesirable and/or pathologic complement activation, and administering treatment to treat undesired complement activation if the detected level is above the reference level. Other methods of detecting complement activation with or without measuring iC3b are also provided.
摘要翻译：检测补体激活的方法，包括在受试者的样品中检测iC3b水平的步骤，其中检测涉及iC3b与非交叉反应性抗体之间的特异性相互作用，将检测到的水平与参考水平进行比较，哪个参考水平在约10ng / ml至约5,000ng / ml的范围内，其中确定检测到的水平高于参考水平表明受试者患有或不期望的和/或病理性补体激活易感，并且对如果检测到的水平高于参考水平，则处理不需要的补体激活。还提供了检测具有或不具有测量iC3b的补体激活的其它方法。

18. 发明申请

US20120135430A1 COMPLEMENT ASSAYS AND USES THEREOF 有权
标题翻译：补充测定及其用途
公开(公告)号：US20120135430A1
公开(公告)日：2012-05-31
申请号：US13321522
申请日：2010-05-21
申请人： Zhouning Zhang , Cedric Francois , Pascal Deschatelets , Paul Olson
发明人： Zhouning Zhang , Cedric Francois , Pascal Deschatelets , Paul Olson
IPC分类号： G01N33/577 , G01N33/566
CPC分类号： G01N33/566 , C07K16/18 , G01N33/564 , G01N33/6893 , G01N2333/4716 , G01N2800/16 , G01N2800/164 , G01N2800/50 , G01N2800/52 , G01N2800/7042
摘要： The present invention provides methods for assessing complement activation and methods for assessing the ability of an agent or condition of interest to modulate complement activation. The present invention provides methods for assessing whether a subject has or is at increased risk of developing a complement-mediated disorder, e.g., age-related macular degeneration (AMD). Also provided are kits containing materials useful for performing the methods.
摘要翻译：本发明提供了用于评估补体活化的方法和评估感兴趣的药剂或病症调节补体活化能力的方法。本发明提供用于评估受试者是否具有发生补体介导的病症（例如年龄相关性黄斑变性（AMD））的风险增加的方法。还提供了包含用于执行方法的材料的试剂盒。

19. 发明申请

US20110182877A1 SUSTAINED DELIVERY OF COMPSTATIN ANALOGS FROM GELS 审中-公开
标题翻译：保持从凝胶中输送共聚物模拟物
公开(公告)号：US20110182877A1
公开(公告)日：2011-07-28
申请号：US12681392
申请日：2008-10-02
申请人： Cedric Francois , Pascal Deschatelets , Paul Olson
发明人： Cedric Francois , Pascal Deschatelets , Paul Olson
IPC分类号： A61K38/08 , A61K39/395 , A61K38/10 , A61P27/02
CPC分类号： A61K9/0051 , A61K38/12 , A61K47/42
摘要： The present invention features the sustained delivery of compstatin analog and, optionally, an additional active agent, by release from a macroscopic, gel-like deposit formed by administering a liquid solution containing the compstatin analog to an extravascular location in the body of a mammalian subject such as the vitreous chamber.
摘要翻译：本发明的特征在于通过从包含化合物抑制物类似物的液体溶液施用于哺乳动物受试者体内的血管外位置形成的宏观的凝胶状沉积物释放，持续递送化合物类似物和任选的另外的活性剂如玻璃体腔。

20. 发明申请

US20070238654A1 Compstatin and analogs thereof for eye disorders 有权
标题翻译：化合物及其类似物用于眼睛疾病
公开(公告)号：US20070238654A1
公开(公告)日：2007-10-11
申请号：US11544389
申请日：2006-10-06
申请人： Pascal Deschatelets , Paul Olson , Cedric Francois
发明人： Pascal Deschatelets , Paul Olson , Cedric Francois
IPC分类号： A61K38/16 , A61F2/14 , A61K38/10 , A61K38/12
CPC分类号： C07K7/08 , A61F9/0008 , A61K9/0019 , A61K9/0048 , A61K9/0051 , A61K31/00 , A61K31/7105 , A61K38/00 , A61K38/08 , A61K38/10 , A61K38/12 , A61K38/17 , A61K39/3955 , A61K49/0008 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K2319/01 , G01N33/6872 , G01N2333/4704 , G01N2500/04 , G01N2500/20
摘要： The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and/or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.
摘要翻译：本发明的特征在于使用化合物抑制剂和补体抑制类似物来治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性，脉络膜新生血管形成和/或视网膜新生血管形成的其它病症。本发明还提供了包含抑制剂或其补体抑制类似物和第二治疗剂的组合物。本发明还提供了包含抑制抑制剂或其补体抑制类似物和凝胶形成材料例如可溶性胶原蛋白的组合物，以及施用组合物的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式